The Plasmodium serine-type SERA proteases display distinct expression patterns and non-essential in vivo roles during life cycle progression of the malaria parasite by Putrianti, Elyzana D et al.
The Plasmodium serine-type SERA proteases display
distinct expression patterns and non-essential
in vivo roles during life cycle progression of the
malaria parasitecmi_1419 725..739
Elyzana D. Putrianti,1,2‡ Anja Schmidt-Christensen,3†‡
Iris Arnold,2 Volker T. Heussler,3 Kai Matuschewski1,2
and Olivier Silvie1,2*
1Parasitology Unit, Max Planck Institute for Infection
Biology, 10117 Berlin, Germany.
2Department of Parasitology, Heidelberg University
School of Medicine, 69120 Heidelberg, Germany.
3Bernhard Nocht Institute for Tropical Medicine,
Department of Molecular Parasitology, 20359 Hamburg,
Germany.
Summary
Parasite proteases play key roles in several funda-
mental steps of the Plasmodium life cycle, includ-
ing haemoglobin degradation, host cell invasion
and parasite egress. Plasmodium exit from
infected host cells appears to be mediated by a
class of papain-like cysteine proteases called
‘serine repeat antigens’ (SERAs). A SERA subfam-
ily, represented by Plasmodium falciparum SERA5,
contains an atypical active site serine residue
instead of a catalytic cysteine. Members of this
SERAser subfamily are abundantly expressed in
asexual blood stages, rendering them attractive
drug and vaccine targets. In this study, we show by
antibody localization and in vivo ﬂuorescent
tagging with the red ﬂuorescent protein mCherry
that the two P. berghei serine-type family members,
PbSERA1 and PbSERA2, display differential ex-
pression towards the ﬁnal stages of merozoite
formation. Via targeted gene replacement, we gen-
erated single and double gene knockouts of the
P. berghei SERAser genes. These loss-of-function
lines progressed normally through the parasite life
cycle, suggesting a specialized, non-vital role for
serine-type SERAs in vivo. Parasites lacking
PbSERAser showed increased expression of the
cysteine-type PbSERA3. Compensatory mecha-
nisms between distinct SERA subfamilies may
thus explain the absence of phenotypical defect in
SERAser disruptants, and challenge the suitability
to develop potent antimalarial drugs based on spe-
ciﬁc inhibitors of Plasmodium serine-type SERAs.
Introduction
Intracellular pathogens have evolved numerous strate-
gies to exit their host cells after completion of replication
and growth and depletion of host cell nutrients (Hybiske
and Stephens, 2008). Cellular exit is often an active bio-
logical process triggered by the pathogen and accompa-
nied by consecutive breaching of the membrane of the
parasitophorous vacuole (PV) that harbours the pathogen
and the host cell plasma membrane.
Plasmodium and other apicomplexan parasites are
obligate intracellular pathogens that need to efficiently
enter and exit their respective host cells in order to propa-
gate and progress along the life cycle. Studies with broad-
spectrum cysteine inhibitors have indicated central roles
for proteolytic events during egress of merozoites, the
invasive stage of the malarial parasite in the pathogenic
red blood cell cycle, out of the PV and the erythrocyte
plasma membrane (Salmon et al., 2001; Wickham et al.,
2003). Plasmodium appears to compartmentalize pro-
teins that function speciﬁcally in parasite egress in
specialized electron-dense secretory organelles termed
‘exonemes’ (Yeoh et al., 2007). Exonemes contain the
subtilisin-like serine protease subtilase 1 (SUB1) that is
essential for parasite growth and can proteolytically acti-
vate a family of papain-like proteases termed ‘serine-
repeat antigens’ (SERAs), which in turn may mediate
parasite egress through subsequent processing of cellular
substrates. Therefore, exoneme discharge may trigger a
proteolytic cascade that ultimately leads to cytolysis and
parasite exit (Yeoh et al., 2007). Understanding the cellu-
lar roles of SERAs, which constitute major substrates of
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cellular microbiologySUB1, may ultimately lead to the identiﬁcation of parasite
and/or host cell substrates and the underlying molecular
mechanisms of proteolysis. Direct support for the pro-
posed roles for SERAs in parasite egress comes from
experimental genetics. Loss of PbSERA5/ECP1 function
results in viable and motile sporozoites that are defective
in exiting the midgut oocyst in the insect vector (Aly
and Matuschewski, 2005). Remarkably, members of the
SERA multigene family appear to have arisen from mul-
tiple gene duplication events. In P. falciparum eight out of
nine SERAs are located in tandem on chromosome 2
(Aoki et al., 2002; Miller et al., 2002). Similarly, in the
rodent malaria model parasite P. berghei the ﬁve SERAs
are tandemly arranged in a head-to-tail fashion on chro-
mosome 3 (Kooij et al., 2005).
This gene organization is evolutionary conserved and is
a hallmark of the SERA multigene family (Arisue et al.,
2007; McCoubrie et al., 2007).
All Plasmodium SERAs contain a central, papain-like
protease domain and numerous cysteine residues.
Intriguingly, this class of proteins appears to be absent in
a number of related apicomplexan parasites, such as
Toxoplasma gondii or Cryptosporidium parvum, suggest-
ing that their respective roles are restricted to malaria
parasites. Despite their overall sequence similarity in their
central protease domain, Plasmodium SERA proteins can
be classiﬁed into four major groups that form two distinct
phylogenetic clusters (Hodder et al., 2003; Kooij et al.,
2005; Arisue et al., 2007; McCoubrie et al., 2007). The
active site cysteine SERAs (SERAcys) form three sepa-
rate groups within one cluster, whereas those with an
active site serine (SERAser) form a fourth monophyletic
group.
The three orthologous SERAcys groups appear to be
well conserved across the genus Plasmodium.T w o
groups, represented by P. falciparum PfSERA6 and
PfSERA7, respectively, are expressed in asexual para-
sites, whereas the third and most ancestral group, repre-
sented by PfSERA8, is not (Aoki et al., 2002; Miller et al.,
2002). Targeted gene deletion of the P. berghei orthologue
of PfSERA8, termed ‘egress cysteine protease 1’ (ECP1),
conﬁrmed a dispensable role in the mammalian host and
instead revealed an essential function for sporozoite
egress from oocysts in the mosquito vector (Aly and
Matuschewski, 2005). By analogy, members of the
PfSERA6 and PfSERA7 groups may function in parasite
egress out of mammalian host cells.
In contrast, the cellular roles of SERAser proteins,
which together form the most diverse group, remain
largely unsolved. The founding member PfSERA5 local-
izes to the PV of mature schizonts (Delplace et al., 1987;
Miller et al., 2002). Puriﬁed recombinant PfSERA5 protein
exhibits only limited chymotrypsin-like autoproteolytic
activity and cleavage of polypeptide substrates is negli-
gible (Hodder et al., 2003). However, this group stands
apart, because (i) expression analysis revealed that
SERAser genes, particularly SERA5, are very abundantly
expressed in P. falciparum late trophozoites and sch-
izonts, the parasite stages preceeding parasite egress
from their host erythrocytes (Aoki et al., 2002; Lasonder
et al., 2002; Miller et al., 2002), (ii) antibodies against
PfSERA5 inhibit parasite erythrocytic growth in vitro
through agglutination of merozoites and ruptured sch-
izonts (Pang et al., 1999), (iii) infected individuals in
malaria-endemic areas exhibit high antibody titres against
SERAser proteins, and most prominently SERA5 (Okech
et al., 2001; Aoki et al., 2002; Okech et al., 2006), and (iv)
high anti-PfSERA5 antibody titres correlate with protec-
tion against severe disease (Okech et al., 2006). In a
monkey model immunization with a puriﬁed recombinant
PfSERA5 fragment induces protection against challenge
infection (Inselburg et al., 1991). Therefore, SERAser pro-
teins represent the most promising group of all SERAs for
potential therapeutic and vaccine targets.
In this study, we investigated the cellular roles of
SERAser by experimental genetics in the model rodent
malaria parasite P. berghei. Unexpectedly, we could
exclude an essential role for all SERAser during the P.
berghei life cycle. Our data suggest that this monophyletic
SERA group evolved in the absence of vital roles for the
parasite.
Results
Plasmodium berghei serine-type SERA proteases
The model rodent malaria parasite P. berghei encodes
two members of the SERAser subfamily, PbSERA1 and
PbSERA2 (Aly and Matuschewski, 2005; Kooij et al.,
2005).
Direct sequencing of cDNA from asynchronous blood
stages permitted identiﬁcation of the complete coding
sequences (GenBank accession numbers: EU917224
and EU917225 for PbSERA1 and PbSERA2 respec-
tively). Comparison of the P. berghei orthologues with the
founding member PfSERA5 (PFB0340c) illustrates the
overall amino acid sequence similarity (Fig. 1A) of ~35%
to the human malaria protein. A hallmark of this subfamily
is the replacement of the catalytically active cysteine
residue by a corresponding serine residue (Fig. 1B). The
other amino acids of the catalytic centre, i.e. an amino-
terminal glutamine and a carboxyterminal asparagine, are
well conserved, apart from a histidine residue, which is
changed to a methionine residue in the homologues of
rodent malaria parasites (Hodder et al., 2003; Arisue
et al., 2007; McCoubrie et al., 2007).
In order to initiate a genetic characterization of the
SERAser subfamily, we proﬁled their expression by
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falciparum expression data (Aoki et al., 2002; Miller et al.,
2002), both transcripts are readily detectable in blood
stage merozoites. Both transcripts are absent during
sporozoite maturation and expression commences again
during liver stage development. Both PbSERA1 and
PbSERA2 appear to be abundantly expressed late in liver
stage development (Fig. 2A), as observed previously
(Schmidt-Christensen et al., 2008). Together, these data
suggestthatthetwoSERAsergenesareexpressedduring
formation of liver stage and blood stage merozoites.
We further quantiﬁed the relative transcript abundance
for the ﬁve P. berghei SERA genes using real-time
RT-PCR (Fig. 2B). The two SERAser genes, PbSERA1
and PbSERA2, were the most abundantly expressed in
blood stages. In late liver stages, PbSERA1, PbSERA2
and PbSERA3 were expressed at a similar level, whereas
PbSERA4 transcripts were less abundant. As expected
(Aly and Matuschewski, 2005), PbSERA5 was not
expressed in liver or blood stages (Fig. 2B). These data
conﬁrm that the SERAser genes (and particularly
PbSERA2) are the SERAs most prominently expressed in
blood stages, consistent with P. falciparum expression
data (McCoubrie et al., 2007).
Cellular localization of PbSERA1 and PbSERA2
We next investigated the localization and the expression
timing of PbSERA1 and PbSERA2. For this purpose we
generated parasite lines expressing the endogenous
SERA1 and SERA2 proteins fused to the mCherry red
ﬂuorescent protein (Shaner et al., 2004). This was
achieved by transfection of targeting vectors that contain
an amino-terminally truncated PbSERA1 or PbSERA2
copy and in-frame fusion of the mCherry coding region,
followed by the DHFR/TS 3′ untranslated region (Fig. 3A).
Upon a single cross-over event, integration of these
constructs is predicted to result in an allelic duplication,
resulting in a mCherry-tagged full-length copy and a
non-transcribed 5′ truncated version of the PbSERA1 or
PbSERA2 gene.
Transfection was performed in P. berghei ANKA para-
sites expressing GFP (Janse et al., 2006), leading to
green ﬂuorescent parasites that express a red ﬂuorescent
SERA1 or SERA2 protein. Genotyping by PCR using
speciﬁc primer combinations conﬁrmed the desired inte-
gration events (Fig. S1).
We ﬁrst performed live cell imaging of blood stages
of the transgenic PbSERA1/mCherry and PbSERA2/
mCherry parasites. Similarly to SERA5 in P. falciparum
(Delplace et al., 1987), both PbSERA1/mCherry and
PbSERA2/mCherry were detected in late schizonts, but
not in early blood stages (Fig. 3B). PbSERA1/mCherry
and PbSERA2/mCherry parasites developed normal
asexual and sexual blood stages, and could be trans-
mitted to Anopheles mosquitoes, resulting in the forma-
tion of sporozoites (data not shown). In good agreement
with our transcription analysis, PbSERA1/mCherry and
PbSERA2/mCherry were barely detectable during the
mosquito stages (data not shown).
Fig. 1. The rodent malaria active-site serine SERA subfamily.
A. Primary structure of Plasmodium SERA proteins with active site serines (SERAser). The central papain-like cysteine protease domains are
boxed in grey. Overall amino acid sequence identities of the P. berghei SERA1 (EU917224) and SERA2 (EU917225) sequences are indicated
as percentages of identical residues compared with the P. falciparum SERA5 (PFB0340c). Fragments used for protein expression, puriﬁcation
and antibody production are indicated by bars.
B. Partial conservation of the catalytic residues of the papain family within the central serine protease domain. P. berghei SERA1 and SERA2
and P. falciparum SERA5 are shown together with papain and a P. berghei cysteine family SERA protein, PbECP1/SERA5. The strictly
conserved amino acid residues are boxed in grey, and the putative active-site serine or cysteine is shown in bold and boxed in black.
Additional residues of the active site are marked with an ‘o’. Note that the catalytic histidine is replaced by a methionine. In contrast, the
carboxy-terminal asparagine and the amino-terminal glutamine, which form the oxyanione hole, are conserved.
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SERAs during liver stage development in vitro.A s
observed with blood stages, the fusion proteins were not
detected in early liver stages, but were abundantly
expressed in late liver stages (Fig. 3C and D). Remark-
ably, PbSERA1/mCherry and PbSERA2/mCherry showed
clearly distinct expression patterns in liver stages.
PbSERA1/mCherry was detected in mid and late liver
stages, and localized predominantly to the PV, which con-
stitutes the parasite/host interface (Fig. 3C). In contrast,
PbSERA2/mCherry became detectable only at the end of
liver stage development, with an intracellular distribution
in the parasite (Fig. 3D). Interestingly, PbSERA1/mCherry
was not detected in merosomes, in contrast to PbSERA2/
mCherry, which gave a strong signal associated with
individual merozoites inside merosomes (Fig. 3E). Collec-
tively, these data indicate that both PbSERA1 and
PbSERA2 are expressed in late blood and liver stages.
Importantly, the two proteins apparently distribute to
distinct compartments, and only PbSERA2 remains
associated with merozoites after PV membrane (PVM)
rupture.
To get further insights into the distribution of
PbSERAser proteins, we performed immunoﬂuores-
cence analysis of late liver stages, using antibodies
generated against the C-terminus of PbSERA1 (anti-
SERA1C) or the central domain of PbSERA2 (anti-
SERA2M) respectively (Fig. 1A). In late liver stages,
Fig. 2. Expression proﬁling of P. berghei
SERAser.
A. RT-PCR analysis of SERA1 and SERA2
expression in mosquito midgut (mg) and
salivary gland (sg) sporozoites, mid (24 h)
and late (48 h, 72 h) liver stages, liver
stage merosomes (mer) and blood stage
merozoites (BS mer). The merozoite and
sporozoite-speciﬁc transcripts, MSP1 and
TRAP, and the constitutive GAPDH transcript
were added as controls. cDNAs were
synthesized from mRNA in the presence (+)
or absence (-) of reverse transcriptase.
Genomic DNA (gDNA) was added as an
ampliﬁcation control.
B. Quantitative RT-PCR analysis of P. berghei
SERA gene expression in WT mixed blood
stages (BS), puriﬁed schizonts (late BS) or
infected HuH7 cell cultures 65 h post-infection
(late LS). Relative gene expression was
normalized to MSP1 expression level, and is
shown as the mean of two independent
experiments (SD).
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restricted to the PVM, as shown by colocalization with
the PVM marker exported protein 1 (EXP1) (Fig. 4A,
upper panels). This pattern was also observed at more
advanced stages of development, in cytomeres and fully
differentiated merozoite-containing parasites (Fig. 4A,
middle and lower panels). This distribution is reminiscent
of the ﬂuorescence pattern observed in parasites har-
bouring a mCherry tag at the C-terminus of PbSERA1
(Fig. 3C). In contrast, anti-SERA2M antibodies showed a
more complex distribution in late liver schizonts and
cytomeres, staining both the PVM and more internal
structures (Fig. 4B, upper and middle panels).
Interestingly, in terminal liver stages, just prior to the
release of merozoites, SERA2M was detected at the
periphery of the parasites, in the PV and/or PVM compart-
ment, as well as the host cell cytoplasm (Fig. 4B, lower
panels). This distribution differs from that of the C-terminal
fragment of SERA2, based on the ﬂuorescence pattern in
PbSERA2/mCherry parasites (Fig. 3D). Together, these
results strongly suggest that SERA2 is processed towards
the end of liver stage development, with the central puta-
tive papain-like domain being released in the vacuolar
space, while the C-terminal domain (visualized by the
mCherry tag) remains associated with the merozoites. In
good agreement with this hypothesis, Western blot analy-
sis of puriﬁed blood stage schizonts demonstrated that
SERA2 processed forms were enriched in saponin
extracts, as compared with Triton X-100 (Fig. S2), consis-
tent with localization to the PV compartment of cleaved
products that contain the central domain recognized by
the anti-PbSERA2M antibodies.
Generation of PbSERA1 and PbSERA2
knockout parasites
We next wanted to study the cellular functions of
PbSERA1 and PbSERA2 in the Plasmodium life cycle.
Based on the refractoriness to gene knockout of PfSERA5
(McCoubrie et al., 2007), we expected that at least one
member of the P. berghei SERAser family plays a vital role
during asexual growth and therefore cannot be targeted
by classical reverse genetics. We generated replacement
vectors that were designed to disrupt the corresponding
Fig. 3. Fluorescent tagging of P. berghei
SERA1 and SERA2.
A. Insertion strategy to generate the
SERA1/mCherry and SERA2/mCherry
parasites. The PbSERA1 and PbSERA2
genomic loci were targeted with integration
plasmids containing the 3′ SERA1 and
SERA2 terminal fragments (dark grey box)
that is fused in frame to the mCherry coding
sequence (red box), the 3′ UTR of
PbDHFR/TS (light grey box) and the
TgDHFR/TS selectable marker (white box).
Upon a single cross-over event, the region
of homology is duplicated, resulting in a
functional, endogenous PbSERA1 or
PbSERA2 copy tagged with mCherry,
followed by a truncated and non-expressed
copy.
B. Expression of the mCherry fusion proteins
(red) was analysed by confocal ﬂuorescence
microscopy of SERA1/mCherry and
SERA2/mCherry P. berghei blood stage
parasites constitutively expressing GFP
(green). Parasite stages are indicated by
arrow heads. T, ring/trophozoite; S, schizont.
Nuclei were stained with Hoechst 33342.
Bars, 5 mm.
C and D. Liver stage expression of the
mCherry fusion proteins (red) was analysed
by confocal ﬂuorescence microscopy of
SERA1/mCherry (C) and SERA2/mCherry
(D) P. berghei parasites constitutively
expressing GFP (green), at 24, 48 and 65 h
after infection of HuH7 cells with sporozoites.
Bars, 10 mm.
E. Detached infected cells (merosomes) were
recovered from the supernatant of infected
HuH7 cultures 65 h post infection, and
analysed by confocal ﬂuorescence
microscopy. Size bars, 10 mm.
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tion after transfection into P. berghei parasites (Fig. 5A).
Unexpectedly, we could select recombinant parasite
populations with the antifolate pyrimethamine. Subse-
quent cloning of single parasites resulted in multiple
clonal sera1(-) and sera2(-) parasite lines. Genotyping by
PCR using speciﬁc primer combinations conﬁrmed the
expected recombination events in sera1(-) and sera2(-)
parasite lines (Fig. 5C), and RT-PCR demonstrated the
complete absence of SERA1 transcripts and SERA2 tran-
scripts in sera1(-) and sera2(-) blood stage parasites
respectively (Fig. 5D). Furthermore, Western blot analysis
of puriﬁed blood schizonts demonstrated the absence
of PbSERA1 and PbSERA2 proteins in sera1(-) and
sera2(-) blood stage parasites respectively (Fig. 6). Col-
lectively, these results conﬁrm the successful disruption of
the corresponding gene.
PbSERA1 and PbSERA2 are dispensable during the
parasite life cycle
We then analysed the phenotypes of sera1(-) and
sera2(-) parasites. The successful disruption of SERA1
and SERA2 genes in P. berghei blood stages indicated
that both are dispensable during blood stage multiplica-
tion of the parasite. Both sera1(-) and sera2(-) parasites
produced gametocytes and exﬂagellation of male game-
tocytes was similar to WT parasites (data not shown).
Transmission to Anopheles stephensi mosquitoes and
oocyst development were also normal when compared
with WT parasites (Table 1). Both sera1(-) and sera2(-)
oocysts produced sporozoites, which invaded mosquito
salivary glands as efficiently as WT parasites (Table 1).
These ﬁndings demonstrate that SERA1 and SERA2 are
dispensable for the P. berghei life cycle in the mosquito
vector, in good agreement with the absence of gene
expression in the mosquito stages (Fig. 2A). Sporozoites
from sera1(-) and sera2(-) parasites displayed normal
gliding motility (Table 1), and were infective to rats
(Table 2). Importantly, after intravenous injection of sporo-
zoites or administration through mosquito bites, the
natural transmission route, we observed no delay in
patency as compared with WT parasites (Table 2). This
clearly shows that hepatic merozoites are formed and
released normally in sera1(-) and sera2(-) P. berghei
parasites. This was conﬁrmed by in vitro experiments,
Fig. 4. Immunoﬂuorescence analysis of PbSERA1 and PbSERA2
in late liver stages. P. berghei infected HepG2 cells were ﬁxed at
different time points (45–58 h) post infection and analysed on
single cell level using IFA. Developmental stages are indicated
on the left. Localization of the C-terminal region of PbSERA1 (A)
and the central domain of PbSERA2 (B) were determined using
speciﬁc rat antibodies (red). As a marker for the PVM, we used
chicken anti-EXP1 antibodies (green), and DNA was labelled with
DAPI (blue). Scale bar: 5 mm. Note the distribution of SERA1C to
the PV compartment in all stages, whereas SERA2M localizes both
to the PV and internal parasite structures in schizonts and
cytomeres, but only to the PV compartment after merozoite
differentiation.
Fig. 5. Targeted gene disruption of the P. berghei SERAser genes.
A and B. Replacement strategy to generate the sera1(-) and sera2(-) parasites (A), and the sera1(-)/2(-) parasites (B). The wild-type (WT)
SERAser genomic loci are targeted with KpnI/SacII-linearized replacement plasmids (pREP) containing 5′ and 3′ untranslated regions adjacent
to the SERAser open reading frames and the dhfr/ts-positive selectable marker. Upon a double cross-over event the open reading frame is
replaced by the selectable marker. Replacement-speciﬁc test and WT primer combinations are indicated by arrows and expected fragments as
lines.
C. Replacement-speciﬁc PCR analysis. The successful replacement event is veriﬁed by a primer combination (test) that can only amplify a
signal from the REP locus. Absence of the WT signal from sera1(-), sera2(-) and sera1(-)/2(-) parasites conﬁrms the purity of the clonal
populations.
D. RT-PCR analysis of SERA1, SERA2 and MSP1 transcripts in WT, sera1(-), sera2(-) and sera1(-)/2(-) blood stage parasites. RT-PCR was
performed in the presence (+) or absence (-) of reverse transcriptase (RT). Parasite genomic DNA (gDNA) was included as an ampliﬁcation
control.
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form exoerythrocytic forms (EEFs) in cultures, in numbers
comparable with WT parasites (Table 1). Together, these
ﬁndings demonstrate that individual SERAser are dis-
pensable during the P. berghei life cycle.
P. berghei lacking both SERAser progress normally
through the parasite life cycle
We hypothesized that compensatory mechanisms within
the SERAser subfamily may explain the absence of phe-
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generated parasite lines with a double PbSERA1 and
PbSERA2 gene deletion. To this end, we used a replace-
ment vector containing the 5′ region of PbSERA1, the
selection cassette and the 3′ region of PbSERA2
(Fig. 5B). Remarkably, after transfection of P. berghei
parasites with this targeting construct, we could select
and isolate sera1(-)/2(-) parasite populations. Genotyp-
ing by PCR using speciﬁc primer combinations conﬁrmed
the expected recombination events (Fig. 5C). Further-
more, RT-PCR and Western blot analysis demonstrated
the complete absence of SERA1 and SERA2 transcripts
(Fig. 5D) and proteins (Fig. 6), respectively, in sera1(-)/
2(-) blood stage parasites, conﬁrming the simultaneous
disruption of both SERA1 and SERA2 genes. As
expected, immunoﬂuorescence analysis conﬁrmed the
absence of staining of sera1(-)/2(-) late liver stages with
anti-SERA1 and anti-SERA2 antibodies, which also dem-
onstrates the speciﬁcity of the staining pattern observed in
WT parasites with these antibodies (Fig. S3 and Fig. 4).
Fig. 6. Western blot analysis of PbSERA1
and PbSERA2 protein expression in P.
berghei blood stages. Triton X-100 extracts of
enriched schizont preparations from WT,
sera1(-), sera2(-) and sera1(-)2(-) parasites
were analysed by Western blot using
antibodies speciﬁc for PbSERA1 and
PbSERA2. Anti-HSP70 antibodies were used
as a loading control. Note the absence of
speciﬁc bands (arrows) in the knockout
parasite lines, conﬁrming complete gene
disruption. Non-speciﬁc bands are indicated
with an asterisk.
Table 1. Phenotypic analysis of SERAser(-) mutants.
Experiment
Parasite
population Infectivity
Mean no. of sporozoites/
infected mosquito
Gliding
motility
a EEF 24 h EEF 48 h Midgut
Salivary
glands
I WT 95% 47 000 23 500 ++ 222 (16) 170 (24)
sera1(-) 90% 33 300 30 550 ++ 200 (04) 161 (17)
II WT 85% 17 500 11 200 ++ 235 (19) 131 (12)
sera2(-) 65% 38 100 8 050 ++ 113 (12) 96 (15)
sera1(-)/2(-) 90% 34 550 16 600 ++ 242 (05) 112 (22)
III WT 85% 31 500 14 000 ++ 237 (11) 102 (08)
sera1(-)/2(-) 75% 36 750 11 400 ++ 229 (28) 102 (19)
a. Gliding motility was visualized by CSP labelling of salivary gland sporozoites on glass slides, and motile sporozoites were counted using a
ﬂuorescence microscope.
++, continuous, multiple trails in more than 30% of sporozoites.
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2(-) displayed no obvious defect during asexual blood
stage growth (Fig. 7) and sexual stage differentiation
(data not shown). The double disruptants could be trans-
mitted to mosquitoes, where parasite development was
not affected (Table 1). sera1(-)/2(-) parasites produced
normal numbers of sporozoites (Table 1), which were
motile and as infective to rodents as WT parasites
(Table 2). As observed with single gene disruptants,
sera1(-)/2(-) parasites formed EEFs in vitro, in similar
numbers as WT (Table 1). Furthermore, the number of
detached infected cells released in culture supernatants
was similar between WT (473  200 merosomes per well)
and sera1(-)/2(-) parasites (433  250 merosomes per
well), and mice injected with 500 WT merosomes (n=3) or
sera1(-)/2(-) merosomes (n=3) all developed a patent
blood stage infection at day 2 post injection. Together,
these data establish that in the absence of SERAser, P.
berghei parasites progress normally through their life
cycle. In particular, parasites lacking SERA1 and SERA2
display no detectable defect in egress from infected host
cells.
P. berghei lacking SERAser display increased
expression of the cysteine-type SERA3
Finally, we analysed the impact of SERAser gene disrup-
tion on the expression of the cysteine-type SERAs
PbSERA3 and PbSERA4. Quantitative PCR on cDNA
prepared from puriﬁed blood schizonts showed a modest
reduction of SERA1 transcript levels in sera2(-) parasites,
whereas SERA2 transcript levels were not signiﬁcantly
modiﬁed in sera1(-) parasites. In sharp contrast, in both
sera1(-) and sera2(-) parasites there was an upregula-
tion of PbSERA3, but not SERA4, expression (Fig. 8A).
The increase in PbSERA3 transcript levels was even
more pronounced in parasites lacking both SERAser
(Fig. 8A). To conﬁrm a compensatory upregulation of
PbSERA3 in the SERAser loss-of-function parasite lines
we analysed the protein levels in merozoites (Fig. 8B).
PbSERA3 was detected mainly in saponin extracts, con-
ﬁrming its localization to the PV compartment in blood
stages, as reported previously (Schmidt-Christensen
et al., 2008). In good agreement with the transcript proﬁl-
ing we detected an increase in PbSERA3 protein by 2-
and 2.5-fold in sera1(-) and sera1(-)/2(-) parasites
respectively. These results indicate a potential functional
link between distinct SERA subfamilies, and provide a
possible explanation for the absence of phenotypical
defect in PbSERAser-deﬁcient parasites.
Discussion
The most important ﬁnding from our study is the non-
essential role of the SERAser subfamily in vivo in the
model rodent malaria parasite P. berghei. We successfully
deleted the single genes of SERA1, SERA2 and gener-
ated a SERA1/2 double knockout. Both single mutants
and the double mutant showed no apparent defect at any
phase of the Plasmodium life cycle under standard con-
ditions. Most importantly, the successful generation of the
double mutant demonstrates that redundancy is not an
essential feature of the SERAser family in vivo. This
ﬁnding was unexpected, because SERAser members are
abundantly expressed in asexual blood stages (Aoki
et al., 2002; Miller et al., 2002) and at least one member
Table 2. Infectivity of SERAser(-) mutants to rats.
Parasite
population
Sporozoite
dose
a
No. infected
animals/
No. injected
animals
Prepatency
(days)
b
WT 10 000 8/8 3.3
Mosquito bite 2/2 3.0
sera1(-) 10 000 3/3 3.3
sera2(-) 10 000 2/2 3.5
25 000 2/2 3.5
50 000 1/1 3.0
Mosquito bite 1/1 3.0
sera1(-)/2(-) 10 000 5/5 3.4
a. Sporozoites were either injected intravenously at the doses indi-
cated or delivered by natural mosquito bite via exposure of anesthe-
tized SD rats to 5 infected Anopheles mosquitoes.
b. Prepatency is the time until the ﬁrst detection of an erythrocytic
stage parasite in Giemsa-stained thin blood smears after sporozoite
infection.
Fig. 7. Blood stage growth of sera1(-)/2(-) double knockout P.
berghei parasites. Naïve NMRI mice (n = 5) were injected
intravenously with 1000 wild-type or 1000 sera1(-)/2(-) P. berghei
infected erythrocytes. Infection was then monitored by daily
examination of Giemsa-stained blood smears to determine the
parasitemia.
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be refractory to targeted gene deletion under in vitro
culture conditions (Miller et al., 2002; McCoubrie et al.,
2007). Our ﬁndings suggest that the monophyletic group
of SERAser enzymes serves a specialized and non-
essential role across the genus Plasmodium. Our experi-
mental genetics evidence is supported by the SERA
phylogeny (Arisue et al., 2007; McCoubrie et al., 2007).
Based on available genome sequence data, the avian
parasite P. gallinaceum encodes only for SERAcys
members and appears to have diverged from a common
Plasmodium ancestor prior to a gene duplication event
that formed the two separate phylogenetic clusters. In
good agreement, we now show that the rodent malaria
parasite does not rely on SERAser genes for parasite life
cycle progression. We propose that members of this
monophyletic group evolved gradually and independent of
strong selection pressure for parasite growth. However,
although SERAser do not play any vital function in rodent
malaria parasites, we cannot exclude a role of immuno-
logical pressure in evolution of this family, including its
expansion in the human parasites.
Notably, one important feature distinguishes the P.
falciparum SERAser proteins from their other relatives
(Hodder et al., 2003). In their central domain they retain a
histidine residue that is thought to be part of the catalytic
triad. This residue is generally substituted by leucine in P.
vivax and P. knowlesi SERAser proteins, except for P.
vivax SERA2/P. knowlesi SERA5, and by methionine in
the rodent Plasmodium species. Hence, we currently
cannot formally exclude distinct roles of the histidine-
containing P. falciparum proteins, although their in vitro
proteolytic activity is weak (Hodder et al., 2003). This pos-
sibility can now be addressed experimentally by generat-
ing a trans-species complementation of the PfSERA5
deletion that consistently appears to be required for P.
falciparum growth under in vitro culture conditions (Miller
et al., 2002; McCoubrie et al., 2007). If complementation
with PbSERA1 or PbSERA2 rescues the growth defect,
an essential role for the histidine residue, and perhaps the
PfSERA5 gene as a whole, can be excluded in vivo, and
vice versa. Because of the absence of an apparent
phenotype in the PbSERA1(-)/2(-) double mutant, the
reverse experiment, i.e. complementation with PfSERA5,
would not be informative. Although indirect, such an
approach will eventually substantiate an important in vivo
role for PfSERA5.
Our expression and localization studies with speciﬁc
antibodies and ﬂuorescently tagged parasite lines show
that PbSERA1 and PbSERA2 have distinct expression
patterns, both in terms of expression timing and subcel-
lular localization. After proteolytic processing, N-terminal
and C-terminal parts of SERA proteins remain covalently
linked, while the central domain is released (Li et al.,
2002). The functions of the SERA N- and C-terminal
domains remain unknown. It should be noted that the N-
and C-terminal regions of PbSERA1 and PbSERA2 show
only 34% and 29% amino acid sequence identity, respec-
tively, whereas the central protease-like domain is more
conserved (67% identity). Because in our mCherry con-
structs the ﬂuorescent moiety is fused to the C-terminal
end of SERA1 and SERA2, the fusion proteins only allow
tracking of the C-terminal fragments of the corresponding
SERA, and not the papain-like central domain after pro-
teolytic processing.
Interestingly, by combining C-terminal tagging of
PbSERA2 and antibodies speciﬁc for the central domain
of PbSERA2, we found that the two domains localize to
Fig. 8. Upregulation of PbSERA3 expression in SERAser knockout
lines.
A. SERA gene expression was analysed by quantitative RT-PCR in
puriﬁed schizonts from WT, sera1(-), sera2(-) and sera1(-)/2(-)
parasites. Relative gene expression was normalized to MSP1
expression level, and is shown as the Log2 of the ratio
knockout/WT (mean of two experiments  SD). n.a., no
ampliﬁcation.
B. Saponin (S) or Triton X-100 (T) extracts of puriﬁed schizonts
from WT, sera1(-), sera2(-) and sera1(-)/2(-) parasites were
analysed by Western blot using antibodies speciﬁc for PbSERA3.
As a loading control an anti-HSP70 antibody was used.
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zoites. While the C-terminal region of SERA2 remains
associated with merozoites, the central putative papain-
like domain localizes predominantly to the vacuolar com-
partment. This was also evidenced by differential Western
blot analysis of vacuolar versus parasite protein fractions,
which showed preferential accumulation of SERA2 pro-
cessed forms (containing the central domain) in the vacu-
olar compartment of asexual blood stage parasites. This
suggests that PbSERA2 is proteolytically cleaved at the
end of Plasmodium schizogony, the central domain being
released in the vacuolar space while the C-terminus
remains associated with merozoites.
Differently from PbSERA1/mCherry, which was no
longer detected after PVM rupture, PbSERA2/mCherry
was clearly found associated with liver and blood stage
merozoites. This is reminiscent of PfSERA5 localization
on the surface of free merozoites after processing (Pang
et al., 1999; Okitsu et al., 2007). Although the different
expression patterns of PbSERA1 and PbSERA2 might be
explained by differential stability of their N- and C-terminal
domains after proteolytic processing, our observations
raise the possibility that different SERAs fulﬁll different
functions. PbSERA1 and PbSERA2 are particularly abun-
dant in the ﬁnal stages of liver and erythrocytic schizont
maturation, which is compatible with a potential role in
merozoite egress. Based on their differential localization,
the two P. berghei SERAser may act at different steps of
egress. In such a scenario, PbSERA1, which localizes
predominantly in the PV, could be involved in the rupture
of the PVM. The PbSERA2 C-terminal domain, which
remains associated with merozoites after the PVM
rupture, may rather play a role during subsequent steps,
such as rupture of the host cell membrane or preparation
of merozoites for invasion. Nevertheless, such roles, if
any, can only be auxiliary, because parasites that lack
SERA1 and SERA2 display no defects in egress of liver
and blood stage merozoites, or natural malaria transmis-
sion in general.
So far, only PbSERA5/ECP1 (the orthologue of
PfSERA8) was demonstrated to play a role during para-
site egress. Interestingly, PbSERA5/PfSERA8 stands
apart in the SERA family as it is expressed only in the
mosquito stages and is the only SERA that apparently
lacks a SUB1 cleavage site (Yeoh et al., 2007). In this
regard, it is noteworthy that inhibitors of P. falciparum
SUB1, which cleaves (and presumably activates) SERAs,
are more potent inhibitors of merozoite invasion than of
merozoite egress (Yeoh et al., 2007). While this observa-
tion could be due to different pharmacodynamic pro-
perties of the inhibitors, it is also compatible with a
predominant role of SERAs during merozoite invasion of
erythrocytes rather than parasite egress. The potential
use of several invasion pathways may result in compen-
satory mechanisms explaining why single (and double)
knockout parasites display no obvious defect during their
progression through the life cycle. Because of the
absence of detectable phenotype in parasites lacking
SERAser genes, the loss-of-function approach cannot
discriminate between a role of SERAser proteins during
egress versus merozoite invasion. Gain-of-function
approaches may constitute an alternative strategy,
although it is probably difficult to overexpress SERAser,
which are already highly expressed in normal parasites.
Other strategies such as using blocking antibodies may
help unraveling the function of the SERAser proteins.
Interestingly, we found that P. berghei parasites lacking
both SERAser had increased levels of the cysteine-type
SERA3, both at transcript and protein levels. Although we
cannot formally exclude an effect of the modiﬁcation in cis
of the SERA gene locus in the knockout parasite lines,
this observation suggests a potential functional link
between SERAs belonging to distinct subfamilies. It has
been shown before that P. falciparum parasites with a
deletion of PfSERA4 gene display increased RNA levels
of PfSERA5, which is refractory to gene deletion (McCou-
brie et al., 2007). Similarly, attempts to knockout SERA3
gene in P. berghei remained unsuccessful so far (E.D.
Putrianti, F.F. Masduki, and K. Matuschewski, unpubl.
data), suggesting that PbSERA3 may play an essential
role during P. berghei blood stage infection.
The crystal structure of the central protease-like domain
of PfSERA5 was recently solved, revealing several
anomalies in the active site, in addition to the serine
substitution (Hodder et al., 2009). These structural fea-
tures question the role of SERA5 as an actual protease,
and may explain the limited proteolytic activity of recom-
binant PfSERA5 in vitro (Hodder et al., 2003). In the
absence of a clear proteolytic activity of SERAser proteins
under physiological conditions, multiple non-catalytic cel-
lular roles, including regulatory functions, have to be con-
sidered. An attractive hypothesis is a potential function in
substrate recognition. In analogy to ubiquitin E2-like vari-
ants of the ubiquitin/proteasome pathways that lack active
site cysteine residues and form heterodimers with E2
enzymes (VanDemark et al., 2001), SERAser, while cata-
lytically inactive on their own, could act in concert with
canonical SERAcys proteases and provide crucial sub-
strate binding sites. In such a scenario, the diverse group
of abundant and degenerate SERAser proteins would
bind and recruit substrates to the proteases, thereby
enhancing their overall proteolytic activity in the cell.
While not essential, the presence of multiple substrate
recognition proteins may greatly enhance the adjustment
of the parasite to a changing environment prior to parasite
exit of the respective host cell.
Importantly, a non-vital role in vivo does not exclude the
potential of SERAser members for antimalaria subunit
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essential target antigen, namely MSP3 (Mills et al., 2002),
which shows similar promising characteristics in a
monkey challenge trial and functional assays with sera
from immunized individuals (Hisaeda et al., 2002; Druilhe
et al., 2005). The choice of candidate antigens for incor-
poration into a subunit vaccine does not necessitate an
essential role in the parasite but should rather be based
on functional assays (Matuschewski, 2006). Antibodies
against PfSERA5 inhibit parasite erythrocytic growth
in vitro through agglutination of merozoites and ruptured
schizonts (Pang et al., 1999). Similarly to PfSERA5, the
C-terminal region of PbSERA2 associates with merozoi-
tes, and therefore constitutes a potential target for inhibi-
tory antibodies. In this regard, P. berghei mouse infection
may thus represent a valuable in vivo model to evaluate
antimalarial vaccines targeting SERA antigens. In con-
trast, target validation by reverse genetics to ultimately
prove or disprove that loss of gene function results in
non-viable malaria parasites in vivo is a prerequisite for
preclinical development of tailor-made inhibitors against a
target protein. Our results show that parasites grow nor-
mally in the absence of any SERAser members and cast
profound doubt on the suitability to translate potential
speciﬁc PfSERA5 or other SERAser inhibitors into potent
antimalarial drugs.
Experimental procedures
Experimental animals
Animals were from Charles River Laboratories. All animal work
was conducted in accordance with European regulations
and approved by the state authorities (Regierungspräsidium
Karlsruhe).
Reverse transcriptase PCR
Total RNA was puriﬁed from sporozoites, infected HuH7 cells
or infected erythrocytes using the RNeasy kit (Qiagen). Reverse
transcription was performed using the RETROscript kit
(Ambion). cDNAwas used as template for PCR ampliﬁcation with
primers speciﬁc for P. berghei SERA1 (forward, GTAACTGG
ACAAGAAGAAACACAAG; reverse, CAGGATTGATAGCATA
AACTCTTGAAC), SERA2 (forward, GGTACTCCAGATATGAT
AGTAAATATAATTGG; reverse, GGCCCTGATCCGGAAGATG
AACCTGAAGG), TRAP (forward, CCCGGATCCATGAAGCTC
TTAGGAAATAG; reverse, GTGTGGATCCTTCCTGACAAACT
TTAGAAAG), GAPDH (forward, ATGGCAATAACAAAAGTCG
GAATTAATGG; reverse, TGTGGATAGCCAAATCTAAAAGA
CGG), MSP1 (forward, CTGGTTTGGTAGGAGAAGGCGAATC;
reverse, AGCTACAGAATACACCATCATAAT). Real-time qPCR
was performed on cDNA preparations from mixed blood stages,
puriﬁed blood stage schizonts or late liver stages in HuH7 cell
cultures, using the ABI 7500 sequence detection system and
Power SYBR Green PCR Master Mix (Applied Biosystems),
according to the manufacturer’s instructions. qPCR was per-
formed in triplicates, with 1 cycle of 95°C for 15 min, followed by
40 cycles of 95°C for 15 s, 55°C for 15 s and 60°C for 45 s.
Standard curves were generated for all primers using WT cDNA
serial dilutions and gave ampliﬁcation efficiencies of 90–100%.
Data were analysed with the SDS 1.3.1 software (Applied Bio-
systems). Relative transcript abundance was normalized to
MSP1 expression. The following primers were used for real-time
PCR: SERA1 (forward, CAAGTGGGTATAAGACTAGAATTTA
TGC; reverse, AATTGGCATATACTCCATTTCGCAGC), SERA2
(forward, ACACAAGGTCAAGCCCCACAAAGCC; reverse, CCC
ACCATTTTCTGGAGTTTCAACG), SERA3 (forward, GTTGAT
GTTTTAGGTCCAGATAATTGTG; reverse, GTGGTAAAAATTT
GAACTGAGTTGTGG), SERA4 (forward, CAATTCAGAAAAA
AATAGACATTACCC; reverse, TTTAAACCAATACTTTGTACC
CTCGAAC), SERA5 (forward, CCAAACTGATTTGACTGTAA
CTATAGG; reverse, ATAACTTCACTGTGCATGCATGTGTCG),
MSP1 (forward, AAATAAATCTGGTTTGGTAGGAGAAGG;
reverse, CCGCAGTTTGACAACCAGCAGTTGG).
Generation of the mCherry-tagged SERA1 and SERA2
parasite lines
For targeted ﬂuorescent tagging of SERA1 and SERA2,a n
integration vector was generated by ampliﬁcation of a PCR frag-
ment using P. berghei genomic DNA as template and primers
mCherry-SERA1for (5′-ATAAGAATGCGGCCGCTACCACATG
AGAATGAATTTGCAGGG-3′; NotI site is underlined) and
mCherry-SERA1rev (5′-GGACTAGTCACATAACAAAAGTAGCA
ATCGTCTG-3′; SpeI site is underlined), or mCherry-SERA2for
(5′-ATAAGAATGCGGCCGCATGTTGGTGATTCATGCCCCG-3′;
NotI site is underlined) and mCherry-SERA2rev (5′-TGC
TCTAGATACAGCGCAAAAGTTACATTCATTATCACC-3′; XbaI
site is underlined). Cloning into the P. berghei transfection vector
that contained the mCherry sequence and PbDHFR/TS 3′ UTR
resulted in plasmids pEDP05 and pEDP06, for tagging of
PbSERA1 and PbSERA2 respectively. The targeting plasmids
were linearized with HpaI and AarI respectively, and parasite
transfection, positive selection, and parasite cloning was per-
formed as described previously (Janse et al., 2006). Integration-
speciﬁc PCR ampliﬁcation of the mCherry-tagged SERA1 or
SERA2 was generated using speciﬁc primer combinations. We
obtained one parasite population each that was used for a sys-
tematic expression and localization analysis. Expression of the
mCherry fusion proteins was analysed through direct detection of
the red ﬂuorescence of mCherry by confocal microscopy.
Hoechst 33342 (Molecular Probes) was used to stain nuclei.
Images were acquired on a Zeiss LSM510 confocal system
(Zeiss, Germany) equipped with visible and UV laser lines, and
processed with Adobe Photoshop software (Adobe Systems).
Generation of anti-PbSERA1 and
anti-SERA2 antibodies
DNA fragments corresponding to the coding sequence of
PbSERA1 C-terminal region (Leu877-Ser1122) and PbSERA2
central (M) domain (Lys
546-Pro
714) were ampliﬁed from P. berghei
cDNAby RT-PCR and cloned into pGEX6P-1 vector (Amersham,
Buckinghampshire, England). Recombinant proteins were
expressed in Escherichia coli BL21 cells (Stratagene) as glu-
tathione S-transferase (GST) fusion proteins, and puriﬁed using
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sham Biosciences). Puriﬁed proteins were used to immunize
Lewis rats along with complete Freund adjuvant, followed by
multiple boosting immunizations. A rat monoclonal antibody was
generated against PbSERA1-C. To this purpose, B cells were
isolated from lymph nodes of one rat immunized against
PbSERA1-C protein and fused to the mouse myeloma cell line
P3X63.Ag8.653. The positive pools of hybridoma cells reacting
with SERA1-C were screened by indirect ELISA. Single-cell
clones were isolated by limited dilution, leading to the isolation of
clone C65 (SERA1C), which was characterized further and found
to bind an epitope (D892-EPASISTQ-E901) at the C-terminus of
PbSERA1.
Western blot analysis
Parasite protein extracts were obtained from P. berghei
Nycodenz-enriched blood stage schizont preparations, after
lysis in saponin followed by Triton X-100, to differentiate the
vacuolar compartment from the parasite fraction, as described
(Schmidt-Christensen et al., 2008). Proteins were separated on
10% SDS-PAGE reducing gels and transferred to PVDF mem-
branes (Amersham). Membranes were probed with anti-SERA1
and anti-SERA2 rat antibodies, anti-SERA3 mouse antibodies
(Schmidt-Christensen et al., 2008) or anti-HSP70 mouse anti-
bodies (Tsuji et al., 1994). Horseradish peroxidase-conjugated
goat anti-rat or anti-mouse antibodies (Sigma) were used for
detection, and bands were visualized by enhanced chemilumi-
nescence (Amersham).
Immunoﬂuorescence assay
For analysis of PbSERAser localization in late liver stages,
infected HepG2 cells were ﬁxed with 4% paraformaldehyde, per-
meabilized with ice-cold methanol and incubated with primary
antibodies against PbSERA1C or PbSERA2M (rat). A chicken
anti-EXP1 antibody was used to stain the PVM. Bound antibodies
were detected using anti-rat Alexa Fluor 594- or anti-chicken
Cy5- conjugated secondary antibodies (Molecular Probes,
Leiden, the Netherlands). Nuclei were visualized with DAPI
(Sigma-Aldrich, Germany). Immunoﬂuorescence labelled cells
were examined by confocal microscopy using the Olympus
FV1000 (SIM scanner and spectral detection).
Generation of the seraser knockout parasite lines
For targeted replacement of PbSERA1, a replacement vector
was generated by ampliﬁcation of two PCR fragments using P.
berghei genomic DNA as template and primers SERA1_forI
(5′-GGGGTACCCCCATACCATCACCCCCTTCAAC-3′; KpnI site
is underlined) and SERA1_revII (5′-GCCCAAGCTTCCAGTT
CTCCCGTACCTTCAACCACC-3′; HindIII site is underlined) to
amplify the 5′ ﬂanking region, and SERA1_forIII (5′-CGCG
GATCCGTTGGCAAAGGGGAATATATCGTATCA-3′; BamHI site
is underlined) and SERA1_revIV (5′-TCCCCGCGGCGAATTTT
TACAACTTAAACCATAGTGCAC-3′; SacII site is underlined) for
the 3′ ﬂanking region respectively. Similarly, for replacement of
PbSERA2 we employed primers SERA2_forI (5′-GGGGTACC
GAACCGTTTTTAGGTCGATACGTTCTGTGCTG-3′; KpnI site
is underlined) and SERA2_revII (5′-GCCCAAGCTTCCCATATA
TTGTTTGACGAACAAAATAC-3′; HindIII site is underlined) as
well as SERA2_forIII (5′-GGACTAGTGGTTCATCTTCCGGA
TCAGGGCCAACACCTT-3′; SpeI site is underlined) and
SERA2_revIV (5′-TCCCCGCGGTTGAGATTGGGGGCATGCT
TTTATTACCA-3′, SacII site is underlined). The targeting vector
to generate the SERA1/2 double mutant was cloned from the
5′ ﬂanking region of SERA1 and 3′ ﬂanking region of SERA2
fragments. Cloning into the P. berghei transfection vector (Thathy
and Ménard, 2002) resulted in plasmids pEDP01, pEDP02 and
pEDP03 for pSERA1(-), pSERA2(-) and pSERA1(-)/2(-)
respectively. The targeting plasmids were linearized with
KpnI/SacII, and parasite transfection, positive selection and para-
site cloning were performed as described previously (Janse
et al., 2006). Transfections were performed in the P. berghei
ANKA strain, except for sera2(-) parasites, which were gener-
ated in the P. berghei NK65 strain. Replacement-speciﬁc PCR
ampliﬁcations of the corresponding SERAser(-) loci were gener-
ated using speciﬁc primer combinations. We obtained four, ﬁve
and four independent sera1(-), sera2(-), and sera1(-)/2(-) clonal
parasite populations, respectively, that were phenotypically iden-
tical. Detailed analysis was performed with one representative
clone each.
Phenotypical analysis during the Plasmodium life cycle
in vivo
Blood stage development was analysed in vivo in asynchronous
infections using NMRI mice. Gametocyte differentiation and
exﬂagellation of microgametes were detected in mice before
mosquito feedings. Anopheles stephensi mosquito rearing and
maintenance was carried out under a 14 h light/10 h dark cycle,
75% humidity and at 28°C or 20°C respectively. Sporozoite popu-
lations were separated and analysed as described previously
(Vanderberg, 1975). For determination of sporozoite infectivity,
and numbers of midgut- and salivary gland-associated sporozoi-
tes, infected mosquitoes were dissected at days 10, 14 and 17
after feeding respectively. For determination of the infectivity of
sporozoites, infected mosquitoes were dissected at day 17 after
feeding. Sporozoites were liberated from salivary glands and
injected intravenously at the numbers indicated into young
Sprague/Dawley (SD) rats. Patency was checked daily by
Giemsa-stained blood smears.
In vitro experiments
For analysis of gliding motility, sporozoites isolated from infected
mosquito salivary glands were deposited on glass slides coated
with bovine serum albumin, and incubated at 37°C for 30 min.
Trails left behind gliding parasites were then visualized using
anti-CSP antibodies (Potocnjak et al., 1980). For analysis of EEF
development, we used HuH7 cells cultured in DMEM supple-
mented with 10% FCS and antibiotics. P. berghei sporozoites
were added in triplicate wells, incubated for 2 h at 37°C, and
washed off. After 24 or 48 h, EEFs were revealed using primary
antibodies against Plasmodium heat shock protein 70 (HSP70)
(Tsuji et al., 1994).
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Supporting information
Additional Supporting Information may be found in the online
version of this article:
Fig. S1. Genotyping of PbSERA1/mCherry (A) and PbSERA2/
mCherry (B) clonal parasites. Conﬁrmation of the predicted inte-
gration events by diagnostic PCR fragments, tests 1–4 (see
Fig. 3A). Absence of the WT signal conﬁrmed purity of the clonal
parasite lines.
Fig. S2. Processed forms of PbSERA2 localize preferentially to
the PV compartment. Puriﬁed schizonts from WT P. berghei
parasites were lysed in saponin (PV fraction), followed by Triton
X-100 (parasite fraction). Protein extracts were analysed by
Western blot using rat antibodies speciﬁc for the central domain
of PbSERA2. Processed forms of SERA2 enriched in the PV
fraction are indicated with an arrowhead, whereas other speciﬁc
bands are shown with an arrow.
Fig. S3. Immunoﬂuorescence analysis conﬁrms the absence of
SERA1 and SERA2 expression in P. berghei sera1(-)/2(-) para-
sites. HepG2 cells infected with P. berghei WT or sera1(-)/2(-)
parasites at the cytomere stage were stained with antibodies
against PbSERA1 (A) or PbSERA2 (B). PVM was stained with
anti-EXP1 antibodies (cyan), and DNA was labelled with DAPI
(blue). Scale bar: 5 mm.
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